Continuing Medical Education Conferences in Boston
Baby Beats and Breaths: Therapeutic Interventions for the Premature Infant with Cardiopulmonary Compromise is organized by Education Resources, Inc. (ERI) and will be held from Nov 16 - 17, 2019 at Tufts Medical Center, Boston, Massachusetts, United States of America. Credits: • This course meets the criteria for 14.5 contact hours (1.45 CEUs). • Application has been made to the FL PT Association for 17 continuing education hours. Approved provider by the FL Board OT for 17.4 continuing education hours. • Approved provider by the NY State Board of PT for 17.4 contact hours. • Approved provider of continuing education by the American Occupational Therapy Association #3043 for 14.5 contact hours (1.45 CEU's) Intermediate level. • This course meets approval for type 2 CEUs by the TX Board of OT Examiners. CA OTs will receive 14.5 PDUs. • This course is offered for up to 1.45 ASHA CEUs (Intermediate level, Professional area). • This program has been submitted for approval for 14.5 clock hours of continuing education credit by the TX Speech Language Hearing Association (TSHA). • NBCOT professional development provider-14.5 PDUs . • This course meets the criteria for 14.5 hours towards Neonatal Therapy Certification. Description: This dynamic intermediate-advanced course will elucidate the cardiopulmonary implications for the premature or medically-complex infant as related to physiological stability, evolving motor control, sensory stability, and transition to oral motor skills that support feeding. Participants will learn to facilitate the infant’s ability to cough, produce audible phonation, develop oral motor skills, and improve swallowing skills, as well as gestation-age appropriate positioning and handling to support gross motor skills required for postural stability. This course will focus on the cardiopulmonary implications for the premature or medically-complex infant as related to physiological stability, evolving motor control, sensory stability, and transition to oral motor skills that support feeding. It will focus on advancing the critical reasoning skills of the neonatal therapist to support the infant’s ability to obtain foundational motor and sensory skills. These skills include the ability of the infant to cough, produce audible phonation, oral motor skills, swallow skills, trunk facilitation, gestational age appropriate positioning/handling to support the emergence of gross motor skills for postural stability. You will learn movement analysis skills (via lab time and video presentations) to assess breathing patterns, facilitation techniques to support trunk development, positioning strategies to support chest wall development, and feeding techniques to maximize postural control. We will discuss current literature as relevant to this topic and apply a systems theory approach for case study treatment planning. Course Objectives: Upon completion of this course, participants will be able to do: • Discuss anatomical and kinesiological developmental changes for the newborn chest wall • Discuss the effects of prematurity and cardiopulmonary co-morbidities on chest wall development • Integrate chest wall movement assessment and treatment strategies to maximize infant outcomes • Design developmental positioning and handling interventions to reduce chest wall deformities • Incorporate postural support with positioning and handling of infants for improved chest wall mobility during oral feeding • Integrate a systems approach to individualized care plan for the infant with cardiopulmonary compromise.
Tumor Immunology and Immunotherapy Conference is organized by American Association for Cancer Research (AACR) and will be held from Nov 17 - 20, 2019 at Boston Marriott Copley Place, Boston, Massachusetts, United States of America. Additional details will be posted as soon as they are available.
Nov 18 - 20, 2019 | USD $3997 | Pharmacy and Medicine
3rd Annual Anti-Fibrotic Drug Development (AFDD) Summit is organized by Hanson Wade and will be held from Nov 18 - 20, 2019 at Revere Hotel Boston Common, Boston, Massachusetts, United States of America. Description: With 3 days of in-depth cutting-edge case studies and the highest calibre of industry and academic discussions, 3rd Anti-fibrotic Drug Development Summit (AFDD) will provide the roadmap to anti-fibrotic drug development success. Hear from pharma and biotech companies of all sizes, as well as clinicians and leading academics for a complete picture of the current challenges and opportunities. Find commonalities across disease areas that can be applied back at the lab with presentations from specialists across all fibrotic conditions including NASH, IPF, CKD, cardiovascular, gastro-intestinal, Scleroderma, rare disease and ocular fibrosis. This year’s AFDD Summit will help you to: • Gain insights into the latest novel molecules and pathways to identify the best fibrotic mechanism to target • Explore opportunities for combination therapies in fibrosis and oncology • Ensure successful translation from in vivo and in vitro models to clinical trial through the consistent application of biomarkers and clinical endpoints Time: 8:30 am - 4:30 pm Additional details will be posted as soon as information available.
1st RNA Editing Summit 2019 is organized by Hanson Wade and will be held from Nov 19 - 20, 2019 at Revere Hotel Boston Common, Boston, Massachusetts, United States of America. Description: As CRISPR genome editing struggles to overcome key specificity and delivery challenges in its pursuit to realize therapeutic applications, the 1st RNA Editing Summit 2019 accelerates the translation and commercialization of RNA editing for an array of research and therapeutic applications. As the therapeutic potential of RNA editing explodes, discover the fundamental mechanisms of RNA editing, such as recruiting endogenous ADARs with encodable guideRNAs, and learn about the novel approaches being developed to precisely and efficiently deliver intended RNA edits. Join RNA, functional genomic, cell biology and immuno-oncology experts from large pharma, biotech and academia at the 1st RNA Editing Summit 2019 in the pursuit of translating emerging RNA editing mechanisms into therapeutic reality. Top 3 benefits of attending: • Tap into the genetic engineering eruption that is occurring and gain first mover advantage in this fast emerging space learning from leading biotech’s and pioneering academics. • Discover the fundamental mechanisms of RNA editing and learn about the novel approaches being developed to precisely and efficiently deliver intended RNA edits. • Explore how RNA Editing can be used as a critical immuno-oncology tool and unravel different industry approaches to utilize or inhibit these enzymes for the treatment of human diseases. Time: 08:00 - 17:00 Additional details will be posted as soon as information is available.
Nov 19 - 21, 2019 | USD $2299 | Pharmacy and Medicine
4th Annual CDD for Biologics is organized by Hanson Wade and will be held from Nov 19 - 21, 2019 at Revere Hotel Boston Common, Boston, Massachusetts, United States of America. Pre-Conference Workshops: Workshop A Tuesday, November 19 9:00 am - 12:00 pm Implementing Machine Learning and AI Technologies Workshop B Tuesday, November 19 1:00 pm - 4:00 pm In-silico Immunogenicity Predictions (Hands-on Session) Description: What if you could improve on nature? Biologics have always sought to exploit the ingenuity of the human body but now more than ever there is a chance to add to that. Powerful in silico tools exist to improve the selection of favorable molecules and optimize their attributes from early discovery through to late-stage candidate optimization. The 4th annual CDD for Biologics Summit gathers the computational thought leaders in biopharma, academia and software providers along with the end-users in computational biology, structural biology and bioinformatics to debate how to add immediate value to biologics pipelines. Join us to learn how to improve predictability of target ID and validation, better understand protein/protein interactions, enhance rational candidate selection and optimize developability characteristics. How could your pipeline benefit? Welcome to the CDD for Biologics Summit Recent advances in data availability and breakthroughs in computational power have given scientists new opportunities to optimize the discovery, design and developability of biotherapeutics. However, with their utility lacking comparatively behind the small molecule space, there remains an ever-present need to address current capabilities amongst the scientific and operational challenges that exist. With input from the likes of BMS, MedImmune, EMD Serono, Denali & Kadmon; CDD for Biologics has been specifically designed to help biopharma companies define strategies to further adapt these tools, mitigate data availability issues and address computational-experimental challenges to add immediate value to their biologics pipelines. Join us, as our expert speaker faculty shares the very latest insights into how these tools are being utilised to enhance cost-effectiveness, shorten biologics development timelines and accelerate program development.
Nov 19 - 21, 2019 | USD $4396 | Genetics
Gene Therapy Analytical Development Summit is organized by Hanson Wade and will be held from Nov 19 - 21, 2019 at The Westin Copley Place, Boston, Boston, Massachusetts, United States of America. Description: In the context of unprecedented gene therapy clinical progress and mounting regulatory scrutiny, the inaugural Gene Therapy Analytical Development Summit will unite large pharma and innovative biotechs to develop robust analytical tools to guarantee the consistency, quality and safety of gene therapy products. Focused specifically on addressing the unique analytical challenges posed by gene therapy vectors, this technical scientific meeting will unite the ‘boots on the ground’ scientists grappling with these challenges first-hand. Delving into technical analytics to assess potency, capsid integrity, empty vs full capsids and viral titers of AAV and lentiviral vectors, this is your opportunity to enhance your existing analytical methods and explore innovative novel tools to support safe and effective gene therapy development. Pre-Conference Workshops: Workshop A Date: Tuesday, November 19 Time: 8:00 am - 11:00 am Enhancing Analytical Comparability Strategies to Support Every Stage of Development Whatever stage of development you’re currently at, progressing to the next phase and adapting your analytical strategy is a key challenge you will need to navigate. This is all in the context of increasing regulatory scrutiny and uncertainty over the analytical and comparability strategies required to satisfy the regulators. Workshop B Tuesday, November 19 11:30 am - 2:30 pm Discussing How to Develop Accurate Assays to Measure Residual Impurities Analyzing both DNA and protein impurities is a key aspect of gene therapy analytical investigation. It’s clear that there are numerous challenges involved in this analysis, that limit the potential to establish methods that capture the extent and diversity of impurities present. Workshop C Tuesday, November 19 3:00 pm - 6:00 pm Investigating Outsourcing Strategies to Utilize Internal and External Resources Effectively Establishing mutually beneficial collaborations with external organizations is a key factor in long-term success. Given the complexity of gene therapy analytics, establishing these relationships is a complex task and decisions around when as well as what to outsource are key. This workshop will provide an opportunity for in-depth discussions from those who have been intimately involved in this aspect of this field.
3rd Annual Dermatology Drug Development Summit is organized by Hanson Wade and will be held from Nov 19 - 21, 2019 at Aloft Boston Seaport District, Boston, Massachusetts, United States of America. Enhancing the Development and Bringing to Market of New Dermatological Therapeutic Options Description: The Dermatology Drug Development Summit series is a unique industry-focused forum dedicated to innovating, accelerating and sharing pharmaceutical best practice on the development and bringing to market of new dermatological drugs, in the treatment of high unmet need. The dermatology space continues to undergo huge therapeutic innovation and growing competitive pressure, driven by the evolving understanding of the pathophysiology of skin diseases, as well as in the available treatment options for chronic, moderate to severe dermatological conditions and high unmet need that affects the lives of patients worldwide. The 3rd Annual Dermatology Drug Development Summit provides leading industry experts with a unique forum to debate the end-to-end challenges in dermatology drug development: from discovering new research on key disease pathways, to unveiling critical preclinical insights, discussing formulation strategies, defining the optimal clinical development plans or evaluating commercialization approaches. Key Benefits of Attending: • Accelerate the development of innovative dermatological therapies • Hear from KOLs how to tackle the challenges to bring better dermatology drugs to market • Be in tune with growing excitement in the dermatology drug development space Key Highlights You Cannot Miss: • Incyte Corporation • LEO Pharma • Galderma • Sienna Biopharmaceuticals • FDA • Krystal Biotech • Incyte Corporation • Dermavant Sciences Pre-Conference Workshop Day - Tuesday (Nov 19, 2019) Workshop A- 8:00am – 10:45am Novel Translational & Clinical Development Approaches For Topicals In this workshop, real-life data and hypothetical examples will be used to explore alternative strategies for early development of topical products. Cases will be shown illustrating how the measurement of real-time PK/PD, establishing proof-of-pharmacology in challenge models, or assessing safety via dermal PK can be applied to de-risk development and build confidence. Workshop B- 11:00am – 1:45pm The Future of Drug Development in Dermatology: Indications & Implications Key topics to be addressed include: • Current and future dermatology drug landscape • Differentiation strategies in the busy development space • Unmet-need-driven innovation • Building patients’ perspectives into the foundation of product strategy • Acceleration of the drug development process Workshop C- 2:00pm – 5:00pm A key area of focus for drug developers working in dermatology is to ensure the optimization of drug delivery platforms and formulation approaches. In this workshop, you will have the opportunity to gain in depth insights from leading experts in this space that will help you advance your topical development. Start-Up Focus Roundtable - 5:15pm – 7:00pm Backing the Bet: Exploring the Challenges of Funding Development The session will explore key topics, including: • Going public vs staying private • Judging the macro environment • The stories investors buy Additional details will be posted as soon as information is available.
4th Annual NeoAg Summit is organized by Hanson Wade and will be held from Nov 20 - 22, 2019 at The Colonnade Hotel, Boston, Massachusetts, United States of America. Description: The NeoAg Summit is the only industry-dedicated meeting focused on the full end-to-end development and commercialization of neoantigen-based cancer immunotherapies. Neoantigen-targeted therapies are fast becoming the hottest area in personalized immunotherapies. With significant breakthroughs in technology, join us as we optimize the discovery and prediction of neoantigens, accelerating the industry to advance into clinic and effectively target tumor indications. The NeoAg Summit brings together the pioneers weaponizing neoantigen immunotherapy and vaccine development to share key clinical data and insights from sample acquisition, all the way through to vaccine manufacturing and market approval. At the NeoAg Summit, we bring together the leading pharma and biotech companies to discuss: • Advance neoantigen prediction approaches • Improve immunogenicity and learn combination strategies • Scale manufacture to improve the commercial potential of personalized therapies Join the leaders from Genocea, Gritstone, Neon Therapeutics, Ziopharm Oncology, Parker Institute for Cancer Immunotherapy, La Jolla Institute for Allergy and Immunology and many more to spur on more efficacious personalised cancer vaccines and cell therapies. Additional details will be posted as soon as they are available.
World Metastasis Summit is organized by Front Line Genomics and will be held from Nov 20 - 21, 2019 at Hyatt Regency Boston, Boston, Massachusetts, United States of America. Why Attend? • Unlock New Therapeutic Avenues • Shape Your Strategy Using Experts • Improve Clinical Success • Make New Connections Description: It’s estimated that 90% of dying cancer patients die from cancer metastasis. There is currently no cure. Less than 5% of cancer funds go towards tackling metastatic cancer. That’s a dire situation for cancer patients and their families, and it needs to change. Unlike some other existing (and fantastic) research-oriented metastatic cancer events, this event is the first to move beyond basic research and focus on the development of effective therapies. Given the urgency of this event, it is crucial that the right people are there. This event will bring together the entire oncology community - pharma, researchers, clinicians and advocates– to create meaningful change for patients. Our speakers include cancer research pioneers such as Bob Weinberg and Bob Kerbel as well as global leaders and decision-makers in translational oncology. This meeting will address a range of incredible new therapeutic opportunities in a friendly, welcoming environment conducive to deep learning and networking. Key Benefits of Attending: • Explore some of the latest scientific insights into the complex metastatic cascade, and gain insight into the most promising therapeutic avenues for drug developers to explore in the near term. • Learn from the successes and failures in metastasis research, with the hope of fostering collaboration throughout the drug discovery pipeline. • Realise how pharma can rise to the challenge and work with experts in pre-clinical modelling to prioritise pre-clinical testing for metastasis. • Hear case studies from experts in immuno-oncology, to understand how we can overcome some of the biggest barriers in translation. • Network among research pioneers and global leaders in translational oncology. Key Topics Include: • Translate metastasis research into the clinic. • Implement metastatic models. • Stop metastasis earlier. • AI and metastasis. • Biomarkers and metastasis. • Dormancy. • Immuno-oncology and metastasis. • Cancer as a metabolic disease. • Overcoming anti-metastatic bottlenecks. • The microbiome and metastasis. • Endpoints and clinical trials. • Leverage data-driven approaches.
Dec 02 - 03, 2019 | Hours 15.00 | USD $1875 | Research and Clinical Research
Advanced Good Clinical Practice: Practical Application and Implementation Course is organized by Barnett International and will be held from Dec 02 - 03, 2019 at Convene at One Boston Place, Boston, Massachusetts, United States of America. Who Should Attend: This course is recommended for experienced Clinical Quality Assurance Professionals, Clinical Research Associates, Project Managers, Investigators, Study Coordinators, and GCP Focused Regulatory Affairs Professionals. Accreditation Information: Barnett International is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Participants will receive 15 hours (1.5 CEUs) of continuing education credit for full participation, including the completion of a pre-test, post-test, and program evaluation Description: This course provides an advanced, in-depth review of the structural elements of Good Clinical Practice (GCP). Participants will learn practical application of GCP regulations and guidelines for critical components of the clinical research process. Incorporating the updates in ICH E6 R2, we will discuss how clinical research team members can implement systems to manage quality throughout the trial process. Specific attention will be given to how quality systems, or a lack thereof, impact overall data quality and regulatory risk. This program is designed for professionals with at least two years of experience in the clinical research industry. Learning Objectives: • Describe the elements of functional Quality Systems for Sponsors, Institutional Review Boards(IRBs), and Clinical Investigators • Identify the universal and local components of GCP • Explain the differences between the legal and procedural elements of GCP • Describe the overlap between GCP and Good Manufacturing Practice (GMP) • Recognize key differences in pharmaceutical, device, and biologics GCP • Examine recent trends in non-compliance • Develop and implement site-specific approaches for corrective action of non-compliance